Fibronectin in the vascular wall promotes inflammatory activation of the endothelium during vascular remodeling and atherosclerosis. These effects are mediated in part by fibronectin binding to integrin α5, which recruits and activates phosphodiesterase 4D5 (PDE4D5) by inducing its dephosphorylation on an inhibitory site Ser651. Active PDE then hydrolyzes anti-inflammatory cAMP to facilitate inflammatory signaling. To test this model in vivo, we mutated the integrin binding site in PDE4D5 in mice. This mutation reduced endothelial inflammatory activation in athero-prone regions of arteries, and, in a hyperlipidemia model, reduced atherosclerotic plaque size while increasing markers of plaque stability.
Introduction
Endothelial basement membranes in stable vessels, consisting primarily of collagen IV, laminins and less abundant species, promote vessel maturation and stability (1, 2) . By contrast, fibronectin (FN) is present at low levels in stable vessels in most tissues but is strongly upregulated in inflammation, developmental and postnatal angiogenesis, and in atherosclerosis, as is its main receptor integrin α 5β1 (3-6). FN has been most studied in atherogenesis, where it contributes to plaque formation (7) . These effects are mediated in part by inhibiting the anti-inflammatory cAMP/protein kinase A (PKA) pathway (8). This occurs through binding of the α5 subunit cytoplasmic domain to the cAMP-specific phosphodiesterase PDE4D5, which results in dephosphorylation of PDE4D5 on an inhibitory site (9). The resultant increase in PDE catalytic activity suppresses cAMP/PKA signaling, thus priming ECs for inflammatory activation.
EC responses to fluid shear stress play major roles in vessel function, remodeling and disease. Shear stress regulates artery remodeling to determine lumen diameter and, during angiogenesis, induces stabilization of vessel sprouts once flow is re-established (10, 11). Disturbed flow patterns that arise in regions of arteries that curve sharply or branch induce local EC inflammatory activation. In the presence of systemic risk factors such as hyperlipidemia, hyperglycemia, hypertension and elevated inflammatory mediators, these regions selectively develop atherosclerotic plaques. FN gene expression and matrix assembly are induced by disturbed flow (12, 13) . FN is deposited at athero-prone regions of arteries in wild type (WT) mice and increases in atherosclerotic lesions in mice and humans (4, 14) . Deletion of each of the individual isoforms of FN reduces plaque size in mice (15) (16) (17) . However, in the one study where it was examined, deletion of plasma FN also resulted in thinner fibrous caps with evidence of plaque rupture, suggesting reduced plaque stability (17).
Adherence of cells to FN promoted activation of NF-κB and other inflammatory pathways in response to disturbed flow, IL-1β and oxidized LDL, compared to adherence to collagens or laminins (4, 9, 18, 19) .
These effects were reversed by mutation of the integrin α5 cytoplasmic domain in vitro. To test in vivo, 4 we introduced this mutation into mice, where it suppressed atherosclerosis and improved recovery from hindlimb ischemia (9) (20) . EC-specific deletion of integrin α5 also strongly reduced atherosclerosis in mouse models (21) . However, other integrin α 5 cytoplasmic domain effectors may also mediate these effects (22) .
We set out to rigorously test to what extent binding of PDE4D5 to integrin α 5 mediates α 5's role in vascular inflammation and atherosclerosis. Because complete deletion of PDE4D results in neonatal growth retardation and lethality (23), we mutated the integrin binding sequence in PDE4D5 to block this interaction without interfering with other functions. Positive results then prompted us to further examine the mechanism of PDE4D5 regulation. These studies revealed that PDE4D5 regulates a wider array of pathways via effects on phosphatase PP2A and other downstream targets.
Results

PDE4D mut mice
We previously mapped the integrin α5 binding site in PDE4D5 to a short basic sequence (KKKR) in the linker region between the N-terminal UCR2 domain and the catalytic domain (9). Replacement of this sequence with 'EEEE' abolished binding to integrin α5 and blocked the pro-inflammatory effect of FN in vitro. In this study, we aimed to probe its function in vivo by engineering this mutation into mice using CRISPR/Cas9 technology ( Fig 1A) . To minimize off-target mutations, we used the double nicking strategy with Cas9 nickase and two guide RNAs that recognize flanking target sequences (24) (Fig. 1A) .
From 15 pups, sequencing and genotyping identified one mouse with the correct mutation ( Fig. 1B, Fig.   S1A ; 1 female founder, 3 in-del mutants and 11 wild type mice). The mutated allele was successfully transmitted to the next generation ( Fig. S1B ). Homozygous mice were born at the expected Mendelian ratio (WT: 28, Het: 45, Homo: 20) and were viable and fertile, without obvious abnormalities. PDE4D expression was similar in the PDE4D mut compared to wild type mice ( Fig. S1C ).
ECs in atherosclerosis-prone regions of arteries in WT mice show elevated inflammatory markers that coincide with FN accumulation (4, 9) . To investigate effects of the PDE4D5 mutation, longitudinal section of aortas from three-month-old mice were examined for inflammatory markers in the endothelium in the inner curvature of the aortic arch, a well characterized region of disturbed flow that is prone to atherosclerosis when hyperlipidemia and other risk factors are present. As expected, ICAM-1, VCAM-1 and phosphorylated NFκB p65 were all elevated in this region in WT mice (quantified as the ratio of staining relative to the athero-resistant outer curvature in each mouse); these markers were all significantly (ICAM-1) or completely (NF-κB and VCAM-1) suppressed in PDE4D mut mice (Fig. 1C ).
Preventing the binding of PDE4D5 to integrin α 5 thus inhibits vascular inflammation similarly to mutation of the α 5 cytoplasmic domain (25).
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Next, PDE4D mut mice were bred onto the ApoE null background and fed a high fat, "Western" diet for four months to induce atherosclerotic lesions. The PDE mutation had no effect on serum lipids (Fig. S2A ).
Oil red-O staining of aortic roots showed that atherosclerotic lesions were significantly reduced in PDE4D mut /ApoE null compared to WT/ApoE null mice ( Fig. 2A ). CD68 staining for macrophages was similarly reduced (Fig. 2B ). Previous studies showed evidence of plaque vulnerability after deletion of plasma FN (26). However, smooth muscle actin, quantified per plaque area, was increased by 50% in PDE4D mut mice (Fig. 2F) ; picrosirius red staining for fibrillar collagen was also higher in PDE4D mut mice ( Fig. 2C) . By contrast, MMP-2 and MMP-9 per area of plaque were reduced ( Fig 2D, E) , as was MMP activity (Fig. S2C ). Together, these data show that mutation of the integrin binding site in PDE4D5 reduces atherosclerotic lesion size and inflammatory status in hyperlipidemic mice while increasing markers of plaque stability. These results provide definitive evidence that PDE4D5 is a critical integrin α 5 effector in this pathway.
Recovery from restriction of arterial flow occurs via both flow-dependent arteriogenesis and ischemia/VEGF-induced angiogenesis (27, 28) . As FN has been implicated in both processes (5, 6, 28, 29) , we tested PDE4D mut mice in the hindlimb ischemia model where ligation of the femoral artery induces ischemia-independent flow-dependent arteriogenesis in the upper leg and ischemia-induced angiogenesis in the lower leg (30). Three month old wild type or PDE4D mut mice were subjected to femoral artery ligation and blood flow recovery was monitored by laser Doppler imaging. Blood flow recovery was modestly but significantly enhanced in PDE4D mut mice 7 days after ligation ( Figure 2G , Figure S2D ). MicroCT showed that PDE4D mut mice had higher density of both large and small vessels in the ischemic legs 14 days after surgery ( Figure 2H , I). No differences were observed in vessel density in the control legs ( Figure S2E , F), indicating that these effects occurred only after surgery.
Specifically blocking the PDE4D5-integrin interaction therefore did not limit but instead slightly accelerated vessel remodeling in C57Bl6 mice.
Identification of the PP2A complex that dephosphorylates PDE4D
As PDE4D5 activation appeared to be critical for these effects, we next investigated the mechanism of its activation in more detail. Integrin α5β1 activates PDE4D5 by triggering its dephosphorylation on inhibitory S 651 by PP2A, which suppresses anti-inflammatory cAMP-PKA signaling (9). PP2A however represents a family of enzyme complexes comprised of a catalytic subunit (C), scaffolding subunit (A) and regulatory/targeting subunit (B). There are two C isoforms, two A isoforms, and at least 23 regulatory B subunits that mediate selective substrate binding, subcellular localization and catalytic activity of PP2A holoenzymes (31). PP2A AC-core dimers dynamically associate with B subunits regulated by posttranslational modification such as phosphorylation and methylation of C subunit or by adaptor protein binding (32, 33) .
To identify the specific PP2A complex mediating FN-dependent PDE4D dephosphorylation, we hypothesized that phospho-mimetic mutant (PDE4D5-S651E) would behave as a phosphatase trapping mutant for affinity chromatography. Cells were therefore transfected with GFP-PDE4D5-S651E, detached from the culture dishes and replated on dishes coated with FN or with laminin/coll IV basement membrane protein (matrigel, MG). Lysates were pulled down with GFP-Trap nanobody beads and analyzed by SDS-PAGE and silver staining. We observed a PDE4D5-dependent band at 55kD from cells on FN but not MG (Fig. 3A ). LC-MS proteomics identified the protein as the PP2A-B55α subunit ( Fig S3) . This finding was confirmed by immunoblotting ( Fig. 3B ). Thus, B55α appears to be a FN-specific PP2A regulatory/targeting subunit that binds PDE4D5.
To test its function in this pathway, we knocked down B55α in ECs using two different siRNAs. B55α depletion strongly increased PDE4D5-S 651 phosphorylation, supporting its role in PDE4D5 dephosphorylation ( Fig. 3C ). To test the role of cAMP and PKA, we examined the specific PKA site (S 635 ) on eNOS (34). B55α was therefore knocked down in ECs, which were plated on FN and stimulated by flow. eNOS S635 phosphorylation is normally suppressed by FN (19) but was increased following B55α depletion ( Fig 3D) . Consistent with high cAMP/PKA signaling, NF-κB activation by oscillatory shear stress (OS) was also inhibited ( Fig. 3E ). To test whether the reduced NF-κB activation was mediated by PKA, cells were treated with the specific PKA inhibitor, myristoylated amide. This treatment restored flow-dependent NFκB activation after B55α depletion ( Fig. 3F ).
Together, these results show that the B55α is required for dephosphorylation and activation of PDE4D5, which reduces cAMP/PKA signaling to promote NFκB activation in cells on FN.
B55α directly binds N-terminal domain of PDE4D5
The identification of B55α as the regulatory/targeting subunit that mediates association of the PP2A complex with PDE4D5 at sites of adhesion raises the question, is this interaction direct? We therefore measured binding of purified recombinant B55α to purified recombinant fragments of PDE4D5 ( Fig.   4A ). B55α specifically bound to the N-terminal domain (amino acid 1-122) of PDE4D5 ( Fig. 4B ).
Deleting this region from the S651E mutant of PDE4D5 (which binds PP2A more efficiently than WT; Fig 4C) abolished the interaction with B55α ( Fig. 4C ). Thus, the N-terminal domain of PDE4D5 mediates direct binding.
To test the functional role of this interaction, we asked whether the N-terminal domain is required for PDE4D5 S651 dephosphorylation. Thus, endogenous PDE4D5 was knocked down and cells rescued with WT or the Δ N mutant. PDE4D5 S651 phosphorylation was increased with the Δ N mutant relative to WT protein in cells on FN ( Fig. 4D ). To test its role in inflammatory activation by disturbed flow, we carried out a similar knockdown-rescue protocol and then exposed the cells to oscillatory flow for 2h. As expected, NF-κB activation by disturbed flow was blocked by PDE4D5 depletion and rescued by WT PDE4D5 but not the ΔN mutant ( Fig 4E) . Together, these data show that direct binding of PDE4D to B55α promotes PDE4D5 dephosphorylation, which facilitates EC inflammatory activation by disturbed flow.
FN promotes PP2A-B55α holoenzyme assembly
During these analyses, we unexpectedly observed that plating cells on FN greatly increased the coimmunoprecipitation between GFP-B55α and the catalytic subunit of PP2A compared to non-adherent cells ( Fig 5A) or cells on MG (Fig. 5B ). To confirm these results, we immunoprecipitated endogenous B55α, which also showed increased association with the catalytic subunit when plated on FN relative to MG (Fig. 5C ). To test whether this effect requires PDE4D, we carried out similar co-IP experiments after knockdown of PDE4D. PDE4D5 depletion blocked assembly of the PP2A complex in cells on FN ( Fig. 5D ). Thus, FN promotes the assembly of a PP2A phosphatase complex, which requires PDE4D5.
To our knowledge, this is the first instance where a receptor interaction controls assembly of a phosphatase complex.
These results suggest that B55α may localize to cell-matrix adhesions through its association with PDE4D5. To test this idea, cells expressing GFP-B55α were plated on FN or on MG and examined with or without application of shear stress. Shear stress induced B55α relocalization to adhesions that partially overlapped paxillin ( Fig. S4A, B ). Based on the round shape of the adhesions, we examined whether those adhesions are Spreading Initiation Centers (SICs) that form transiently during cell spreading (35). RACK-1, a SIC marker, showed flow-dependent colocalization with B55α on FN ( Fig.   S4C ). Shear stress induced B55α localization to sites of adhesion occurred preferentially on FN compared to MG (Fig. S4A ). These results suggest that binding of cells to FN promotes PP2A holoenzyme assembly at sites of adhesion through an integrin-PDE4D5-B55α pathway.
Yap dephosphorylation by PP2A-B55α
Cells contain tens of thousands of phosphorylated residues and many fewer phosphatase complexes; the finding that FN and integrin α 5 control assembly of a major phosphatase complex therefore immediately suggests that there may be other functionally relevant substrates. The transcriptional regulator Yap is 1 0 linked to integrin signaling, endothelial inflammation and atherosclerosis (36, 37) . In ECs, disturbed flow induces Yap dephosphorylation, stabilization, nuclear translocation and transcription of target genes including inflammatory mediators (36, 37) . Yap phosphorylation by the upstream kinase LATS1/2 inhibits its function via phosphorylation of S 127 , which results in Yap retention in the cytoplasm (38), and S 381 , which triggers Yap degradation (39). Yap may be dephosphorylated by PP2A in virally transformed cells (40). However the phosphatases that reverse these events under normal circumstances are poorly defined. We therefore examined Yap in our system.
To test whether Yap phosphorylation is matrix-dependent, ECs were plated on FN vs MG. Adherence to FN but not MG triggered rapid Yap S 127 dephosphorylation ( Fig 6A) . Disturbed flow induced Yap phosphorylation in cells on MG, which was completely suppressed on FN ( Fig 6B) . These results indicate that a collagen/laminin basement membrane represses Yap activation, consistent with vascular stabilization, whereas FN promotes Yap activation, consistent with its pro-inflammatory effects.
To test whether these matrix-specific effects involved the PP2A complex, cells were transfected with B55α siRNA. Yap dephosphorylation in cells on FN was prevented by knock-down of B55α ( Fig. 6C -E). Yap dephosphorylation was also blocked by knockdown of PDE4D ( Fig. 6D -E), which was rescued by WT but not the B55α-binding deficient PDE4D-ΔN mutant ( Fig. 6F ). Yap nuclear translocation also increased on FN ( Fig S5A) , which was blocked by knockdown of B55α or PDE4D ( Fig S5B) . Yap S 127 dephosphorylation correlated with induction of Yap target genes, ANKRD1 and Cyr61, which was also blocked by B55α or PDE4D knock-down ( Fig. S5C ). Consistent with reduced Yap S 381 dephosphorylation, the previously reported increase in Yap protein levels under longer term disturbed flow(36) was abolished by knockdown of B55α or PDE4D ( Fig S5D) . Together, these results show that the integrin-PDE4D5-B55α axis controls Yap activity.
To identify the direct PP2A-B55α target in the Hippo-Yap pathway, we first examined the upstream kinase LATS1. In cells on FN, flow decreased LATS1 phosphorylation, however, this was unaffected 1 1 by B55α knock-down ( Fig. S6 ). This result excludes LATS1 and all upstream steps in the pathway.
We therefore examined Yap itself. Immunoprecipitated Flag-Yap associated with both GFP-B55α and endogenous B55α (Fig. 6G ). To test whether Yap is a direct PP2A substrate, we measured Yap dephosphorylation in vitro with purified components. Highly phosphorylated Yap purified from confluent 293T cells was incubated with PP2A catalytic subunit immunoprecipitated from endothelial cells using an antibody (clone 1D6) that specifically recognizes catalytic subunit without bound B subunit (41). Catalytic subunit alone showed negligible activity toward phospho-Yap, however, addition of purified B55α induced dose-dependent Yap S 127 dephosphorylation ( Fig. 6H ). Thus, pYap is a direct, B55α-dependent PP2A target.
These results predict that the previously reported activation and stabilization of Yap in regions of disturbed flow in vivo (36, 37) should require the FN-integrin-PDE4D5-B55α pathway. To test this hypothesis, we compared vessels from WT versus PDE4D mut mice on the ApoE -/background on a chow diet, which have increased vascular inflammation but minimal plaque formation. The increased
Yap accumulation in ECs in the atheroprone inner curvature of the aortic arch from WT mice was significantly blunted in PDE4D mut mice ( Fig. 7A ). Furthermore, expression of Yap target gene, Cyr61
and CTGF in the inner curvature was significantly decreased in PDE4D mt mice ( Fig. 7B , C). Together, these data identify Yap as a direct target of the PP2A-B55α complex that is regulated through PDE4D5.
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Discussion
These results show, first, that blocking the binding of PDE4D5 to integrin α 5 reduced EC inflammatory activation and atherosclerotic plaque burden, and increased plaque stability. Together with the previous findings that mutation of the integrin α 5 cytoplasmic domain inhibited these events, these data provide conclusive evidence that the α 5-PDE4D5 interaction contributes to inflammatory activation of the endothelium and to atherosclerosis. The evidence of increased plaque stability is notable in light of the decreased plaque stability after deletion of plasma FN (26) . FN therefore appears to promote inflammation and plaque expansion through α 5/PDE signaling, whereas the enhancement of plaque stability is separable, probably through FN's role in scaffolding collagen fibrillogenesis (42). The PDE4D5 mutation also slightly improved, or at least did not inhibit, vascular remodeling in the hindlimb ischemia model. The integrin-PDE4D5 pathway, unlike FN itself, may therefore be a suitable therapeutic target.
Investigating the mechanism of PDE4D5 activation led to the unanticipated finding that FN and atheroprone regions of arteries (36, 37) was blunted in PDE4D5 mut mice. As Yap inactivation in ECs potently reduced atherosclerosis in mice (36, 37) , this pathway appears to substantially contribute to the effects of the FN-α5-PDE4D5 pathway in vascular disease.
These experiments were done using matrix proteins adsorbed at low concentrations to rigid glass or plastic, thus, are distinct from the regulation of Yap by matrix stiffness (43, 44) . The results, however, fit with the well-known ability of FN to promote EC cell cycle progression relative to laminin and collagen (45), as well as inflammatory activation (2, 9) . Both mechanical and biochemical signaling mechanisms may contribute in vivo, where atherosclerosis and aging are associated with increased matrix stiffness (46). How specific integrin α5 signaling and matrix stiffness interact to regulate Yap activation and gene expression will be interesting to explore in future work.
Binding of cell-derived FN that contains the alternatively spiced EDA domain, but not plasma FN, to TLR4 has been implicated in flow-dependent vascular inflammation and atherosclerosis (16, 47) .
Supporting this idea, both TLR4 and EDA-positive FN are increased in atherosclerotic lesions (48).
Interestingly, there is considerable overlap between the effects of EDA deletion in these studies and blockade of PDE4D binding in our work. This could be explained if TLR4 pro-inflammatory signaling is dampened by cAMP/PKA, such that EDA-TLR4 signaling requires the integrin α 5-PDE4D pathway.
EDA also promotes FN matrix assembly (49), thus, deletion of the EDA domain may decrease the amount of FN in the vessel wall, thus influencing all FN-dependent pathways.
The molecular mechanism by which PDE4D5 controls B55α-PP2A assembly is unknown. In vitro Yap dephosphorylation experiments indicate that PDE4D5 is not required for the B55α-PP2A assembly in solution, as expected from published data (50). PDE4D5 might block inhibitory factors or protein modifications of B55α to facilitate holoenzyme assembly in vivo. Elucidation of detailed mechanism is an important question for further analysis.
4
Atherogenesis shares features with the physiological vascular remodeling that promotes efficient perfusion of tissues via angiogenesis and modulation of vessel diameter (10, 11). These processes involve changes in the extracellular matrix (ECM), inflammatory activation of the endothelium and recruitment of leukocytes that assist with remodeling, followed by resolution of inflammation and restoration of stable vasculature. EC responses to disturbed flow at artery branches and regions of high curvature may be seen as futile, flow-dependent remodeling that synergizes with systemic inflammatory and metabolic stresses to induce atherogenesis. By contrast, physiological remodeling is suppressed by elevated inflammatory status and metabolic disorders (51-54). It is well-accepted that cAMP/PKA activation is anti-inflammatory and reduces a plaque burden (55-57). However, cAMP/PKA signaling is highly multifunctional with distinct effects in the heart, brain, liver and other tissues, thus, is not an attractive target for systemic therapy. Solving vascular disease requires more precise methods to reduce chronic vascular inflammation without harmful side effects. Interactions within the α5-PDE4D5-PP2A
pathway therefore appear to be promising therapeutic targets.
In summary, our data elucidate a pathway in which FN binding to the integrin α5 subunit recruits PDE4D5 to induce assembly of a PP2A-B55α 1 5
Methods
Generation of PDE4D mut mice
We used the double nicking strategy to minimize off-target effects (24, 58, 59) . Two guide RNA sequences were selected from candidate sequences using algorithm from http://crispr.mit.edu/. Guide A: The DNA template for in vitro transcription of Cas9 mRNA was PCR amplified from pX335, in vitro transcribed and purified as described (58). Cas9 mRNA (100 ng/μl), guide A and guide B sgRNAs (50 ng/μl each), and the ssODN template (100 ng/μl) were microinjected into the cytoplasm of C57Bl/6J zygotes; surviving zygotes were transferred to oviducts of CD-1 pseudopregnant females the day of injection as described (60).
For genotyping, the following primers were used:
Wild type allele: 200 bp PCR product, forward primer: 5'gataccaacttgtagtcaactc3', reverse primer: K  -C  ,  Y  e  h  Y  -T  ,  N  g  u  y  e  n  P  ,  L  i  mu  e  c  o  E  ,  L  o  p  e  z  J  ,  T  h  o  r  o  s  s  i  a  n  S  ,  G  u  a  n  K  -L  ,  L  i  Y  -S  J  ,  a  n  d  C  h  i  e  n  S  .  F  l  o  w  -d  e  p  e  n  d  e  n  t  Y  A  P  /  T  A  Z  a  c  t  i  v  i  t  i  e  s  r  e  g  u  l  a  t  e  e  n  d  o  t  h  e  l  i  a  l  p  h  e  n  o  t  y  p  e  s  a  n  d  a  t  h  e  r  o  s  c  l  e  r  o  s  i . 'KKKR' Figure 1 . PDE4D mut mice showed reduced inflammation in a region of disturbed flow.
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A. Gene editing strategy. Two guide RNA's with Cas9 nickase were used with donor ssDNA to induce the KKKR to EEEE mutation. B. Confirming the mutation. The female founder mouse (1422) identified by PCR with mutantspecific primers in Fig S1A was confirmed by sequencing of genomic DNA. C. Inflammatory markers. Longitudinal sections from aortas from three month old wild type or mutant mice were stained for the indicated inflammatory markers. Images show the inner curvature of the aortic arch. Intensity for each marker in the endothelial layer was quantified as described in Methods and intensity in the inner curvature normalized by signal from the outer curvature. Values are means ± SEM. P value determined by two-tailed t-tests. A. FN promotes B55a binding to PDE4D5. BAECs stably expressing GFP-tagged PDE4D5-S651E were plated on dishes coated with FN or matrigel (MG) for 20 min. Lysates were immunoprecipitated with GFP-Trap. SDS PAGE and silver staining identified a.FN-specific band at ~55kDa, which was identified by LC-MS (Fig. S3) as B55a. B. Confirming proteomic results. PDE4D5-S651E immune complexes prepared as in A were Western blotted for PP2A subunits as indicated. Results are representative of three independent experiments. C. B55α knockdown. BAECs expressing WT GFP-tagged PDE4D5 were transfected with control or B55a siRNAs and plated on FN for 6 hr. Cell lysates were Western blotted for PDE4D S 651 phosphorylation or total PDE4D (n=4). D. BAECs transfected with control or B55a siRNAs were plated on FN and exposed to laminar shear (LS) for 15 min. Flow-dependent S 635 phosphorylation of eNOS was measured by immunoblotting with phospho-specific antibody (n=4). E. BAECs transfected with control or B55a siRNAs were plated on FN and subjected to oscillatory shear (OS) for 2 hr. NF-kB activation was measured by Western blotting for p65 S 536 phosphorylation (n=3). F. BAECs transfected with control or B55a siRNA were plated on FN, treated with or without the PKI 14-22 amide inhibitor (PKI) or dimethylsulfoxide (DMSO), and subjected to OS for 2 hr. NF-kB activation was measured by probing for p65 pS 536 (n=3). A. Schematic representation of PDE4D5 fragments. B. Immobilized GST-tagged fragments of PDE4D5 were incubated with purified B55a, washed and probed for bound B55a (n=3). C. HEK 293T cells were transfected with the indicated GFP-tagged PDE4D constructs. Lysates were immunoprecipitated with GFP-Trap and immune complexes probed for B55a and PP2A-A subunit (n= 3). D. PDE4D5 knockdown BAECs were rescued with WT or N-terminally deleted mutant (DN). Cells were replated on FN and subject to OS for 2 hrs. PDE4D5 S 651 phosphorylation was assayed as in Fig 3 (n=3) . E. The same lysates were probed for p-p65 to assay NF-kB activity (n=8). A. BAECs expressing GFP-B55a were detached and replated on FN or kept in suspension for 20 min. GFP-B55a was immunoprecipitated and PP2A subunits were probed in the immune complexes. Sus; suspension B. BAECs expressing GFP-B55a were replated on FN or MG. GFP-B55a binding with B subunits was assayed as (A). (n=3) C. BAECs were replated on FN or MG. Endogenous B55a was immunoprecipitated and catalytic subunit assessed by Western blotting. D. BAECs transfected with PDE4D siRNA were replated on FN for 20 min. GFP-B55a was immunoprecipitated and catalytic subunit assayed by Western blotting as in (A) (n=3). A. BAECs were detached and kept in suspension (Sus) or replated on the indicated matrix protein for 1 hour. pS 127 -Yap was measured by immunoblotting (n=3). B. BAECs plated on FN or MG for 6 hr were exposed to OS for 2 hr. Yap S 127 phosphorylation was assayed as in A (n=4). C. BAECs transfected with B55a siRNA were detached and replated on FN, then exposed to OS for 2 hr. Yap phosphorylation was assayed as in A (n=3). D, E. HUVECs transfected with B55a siRNA or PDE4D siRNA were detached and replated on FN, then sheared for 2 hr. Lysates were analyzed by Western blotting for pS 127 -Yap (D) or pS 381 -Yap (E). n=3 independent experiments. F. PDE4D5 knockdown BAECs were reconstituted with WT or N-terminally deleted mutant (DN). Cells were replated on FN, subject to OSS for 2 h, and Yap S 127 phosphorylation assayed as in A (n=6). G. BAECs expressing GFP-B55a were transfected with FLAG-Yap and replated on FN or MG for 20 min. Yap was immunoprecipitated with FLAG antibody and probed for B55a. N= 3 independent experiments. H. In vitro phosphatase assay. PP2A catalytic subunit was immunoprecipitated with PP2A C subunit antibody (clone 1D6) and incubated for 30 min at 37℃ with phosphorylated Yap in the presence of increasing amount of purified B55a. Reaction mixtures were immunoblotted for pS 127 A-C. Aortas from PDE4D WT /ApoE null mice or PDE4D mut /ApoE on normal chow were fixed, longitudinally sectioned and stained for DAPI to identify nuclei and for total Yap (A). The adjacent sections were stained for Yap target genes, Cyr61 (B) and CTGF (C). Mean intensity in the endothelial layer of the inner curvature (IC) and outer curvature (OC) was quantified (arbitrary units). *p<0.05 by two-tailed t-test. D. Model for PDE4D-dependent regulation of PP2A and its substrate Yap.
